The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: A Multicenter, Prospective, Randomized Trial
Abstract
Background and Purpose —The optimal intensity of warfarin therapy for secondary prevention of stroke in nonvalvular atrial fibrillation (NVAF) remains unclear. We studied the efficacy and safety of conventional- and low-intensity warfarin therapy in a prospective, randomized, multicenter trial. Methods —The study population consisted of patients with NVAF (<80 years old) who had a stroke or transient ischemic attack. The patients were randomly allocated into a conventional-intensity group (international normalized ratio [INR] 2.2 to 3.5) and a low-intensity group (INR 1.5 to 2.1). They were carefully monitored, and the annual rate of recurrent ischemic stroke and major hemorrhagic complications were compared between the groups. Results —We enrolled 115 patients (mean age 66.7±6.5 years) into the study. Fifty-five and 60 patients were allocated into the conventional- and low-intensity groups, respectively. The trial was stopped after a follow-up of 658±423 days, when major hemorrhagic complications occurred in 6 patients of the conventional-intensity group and the frequency (6.6% per year) was significantly higher than that in the low-intensity group (0% per year, P =0.01, Fisher’s exact test). All of the 6 patients with major bleeding were elderly (mean age 74 years), and their mean INR before the major hemorrhage was 2.8. The annual rate of ischemic stroke was low in both groups (1.1% per year in the conventional-intensity group and 1.7% per year in the low-intensity groups) and did not differ significantly. Conclusions —For secondary prevention of stroke in persons with NVAF, especially in old patients, the low-intensity warfarin (INR 1.5 to 2.1) treatment seems to be safer than the conventional-intensity (INR 2.2 to 3.5) treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Petersen, P., Godtfredsen, J., Boysen, G., Andersen, E., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,820
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Stroke Prevention in Atrial Fibrillation Study. Final results.
(1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
(1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,530
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., Gornick, C. C., Krause-Steinrauf, H., Kurtzke, J. F., Nazarian, S. M., Radford, M. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272002 · Cited by 1,160
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,111
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,067
Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
(1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)83303-x · Cited by 539
(1995) · New England Journal of Medicine · doi:10.1056/nejm199507063330102 · Cited by 425
Ezekowitz (1992) · New England Journal of Medicine · Cited by 266
Antithrombotic Therapy in Atrial Fibrillation
Dunn, M., Alexander, J., de Silva, R., & Hildner, F. (1989) · Chest · doi:10.1378/chest.95.2_supplement.118s · Cited by 264
Contrast sonography for detection of vesicoureteral reflux
Kaneko, K., Kuwatsuru, R., Fukuda, Y., Yamataka, A., Yabuta, K., Katayama, H., & Miyano, T. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92123-7 · Cited by 222
Atrial fibrillation and stroke. Three new studies, three remaining questions
Albers, G. W. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.13.1443 · Cited by 182
Antithrombotic Therapy in Atrial Fibrillation
Laupacis, A., Albers, G., Dunn, M., & Feinberg, W. (1992) · Chest · doi:10.1378/chest.102.4_supplement.426s · Cited by 169
Prevention of stroke in patients with nonvalvular atrial fibrillation
Hart, R. G., Sherman, D. G., Easton, J. D., & Cairns, J. A. (1998) · Neurology · doi:10.1212/wnl.51.3.674 · Cited by 164
Atrial Fibrillation and Stroke
Albers, G. W. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130030006 · Cited by 145
Ueda, K., Hasuo, Y., Kiyohara, Y., Wada, J., Kawano, H., Kato, I., Fujii, I., Yanai, T., Omae, T., & Fujishima, M. (1988) · Stroke · doi:10.1161/01.str.19.1.48 · Cited by 131
Cited by
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · Chest · doi:10.1378/chest.08-0678 · Cited by 751
Metadata
- Authors
- Yamaguchi, T.
- Venue
- Stroke
- Published
- 2000-04
- Volume
- 31
- Issue
- 4
- Pages
- 817-821
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2073423663
- Cited by
- 282
- References
- 20
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.